ABOUT EQIPD

215 College Road
Paramus
NJ 07652
United States

Project Leader

Dr. Emer Leahy

Phone number: +1 914 406 800 8 
Fax:  +1 914 406 809 0

Send message

Project Staff

Dr. Sylvie Ramboz

Phone number: +1 914 406 803 3 
Fax:  +1 914 406 809 0

Send message

Institute presentation

PsychoGenics is a leader in in vivo drug discovery whose capabilities include behavioral testing, electrophysiology, EEG, histology, and microdialysis. Complementing its extensive capabilities are a variety of mouse models, including transgenic models, in areas such as Alzheimer’s disease, Huntington’s disease, Parkinson’s disease and psychosis/schizophrenia. PsychoGenics has also pioneered the translation of rodent behavioral responses into robust, high-throughput, high content phenotyping and its drug discovery platforms, SmartCube®, NeuroCube® and PhenoCube® have led to shared risk partnerships with companies such as Sunovion and Roche and has resulted in the discovery of several novel compounds in clinical trials or advanced preclinical development. High-Throughput Phenotyping and Drug Discovery PsychoGenics has pioneered in vivo phenotypic drug discovery with the development of its high throughput, high content, behavior-based drug discovery platforms which have been employed successfully in shared risk partnerships with major pharma companies including Roche, Sepracor (now Sunovion), and others. There are currently three proprietary platforms, SmartCube®, NeuroCube® and PhenoCube® with new applications and technologies in development. Using its platforms the company can evaluate the behavior of hundreds of mice in a week and can screen tens of thousands of compounds for potential to treat neuropsychiatric disorders. The Company has several partnered drug discovery programs that have emerged from its technologies and include four Phase II programs, one program in Phase I and two more that are expected to go into clinical trials in 2018. Standard Behavioral and Non-Behavioral Capabilities PsychoGenics also has an established profitable preclinical CRO business with more than 160 repeat pharma, biotech and not-for-profit clients internationally. PsychoGenics has expertise in behavioral neurobiology and offers over 70 different behavioral tests used to phenotype rodent disease models and test drug candidates in the following areas: • Psychiatric Disorders (Anxiety, Depression, Psychosis, Mania and ADHD) • Neurodevelopmental disorders (Rett Syndrome, Fragile X, Autism spectrum disorders,) • Seizure disorders (rare seizure disorders including Scn8a, Dravet, Tuberous Sclerosis) • Neurodegenerative Diseases – including tests in transgenic models of ALS, Parkinson’s Disease, Huntington’s Disease, Alzheimer’s Diseases, and Spinal Muscular Atrophy • Pain (visceral, inflammatory, neuropathic and osteoarthritis) • Cognitive Disorders • Drug Abuse • Sexual Disorders • Metabolic disorders The company has also established non-behavioral capabilities in the following areas: • Electrophysiology (ex vivo and in vivo) and Translational EEG • Microdialysis (including in freely behaving mice) and bioanalysis • Quantitative RT-PCR and quantitative western • Receptor occupancy (using a beta imager) • Quantitative immunohistochemistry